Moleculin Biotech Addresses Significant Unmet Need with Glioblastoma Trial

Pharmaceutical company, Moleculin Biotech (Nasdaq: MBRX), has initiated an Investigator-initiated Phase 2 study evaluating WP1066 in combination with radiation therapy for the treatment of glioblastoma. The study is an open-label, multi-arm trial which will measure progression-free survival and the tumor microenvironment following treatment. Moleculin’s share price climbed 6.0% in trading on Wednesday and Thursday after the announcement, before settling at $5.04 on Friday afternoon.

Moleculin’s study is being conducted in conjunction with Northwestern University, and is being funded by the National Institutes of Health (NIH) and BrainUp®, a non-profit organization dedicated to bringing awareness to brain cancer.

Commenting on the news, Dr. Priya Kumthekar, Associate Professor and the Co-Investigator for the study, commented, “There remains a significant unmet need in the treatment of glioblastoma. Based on the data seen to date, we believe that WP1066 in combination with radiation therapy has the potential to address this need and provide patients with a much-needed treatment option. We are pleased to commence this important study with Moleculin.”

Glioblastoma is the most aggressive malignant primary brain tumor with a median survival of only 15 months. Despite advancements for other cancers, the survival rate for glioblastoma has not changed significantly in the last three decades.

Moleculin has been granted Orphan Drug Designation by the FDA for WP1066 for the treatment of brain tumors, and Rare Pediatric Disease Designation for three other pediatric indications.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses. The Company’s lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of viruses, as well as cancer indications including brain tumors, pancreatic and other cancers.

For more information about the Company, please visit www.moleculin.com and connect on Twitter, LinkedIn and Facebook.